Menu Search
Equities

Intelligent Bio Solutions Inc

12Q0:BER

Intelligent Bio Solutions Inc

Actions
  • Price (EUR)0.00
  • Today's Change0.00 / --
  • Shares traded--
  • 1 Year change-100.00%
  • Beta--
Data delayed at least 15 minutes, as of Jan 29 2024 07:25 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Intelligent Bio Solutions Inc. is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its segment includes Commercially available Intelligent Fingerprinting Products and Development Stage Biosensor Platform Technology. Its product portfolio includes Intelligent Fingerprinting Platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader, and a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Biosensor Platform is designed to detect multiple biological analytes by substituting the top enzyme layer of the biosensor to suit each analyte and to develop a range of Point of Care Tests, including the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology.

  • Revenue in USD (TTM)3.11m
  • Net income in USD-10.16m
  • Incorporated2016
  • Employees13.00
  • Location
    Intelligent Bio Solutions Inc135 W 41St St,, Floor 5NEW YORK 10036United StatesUSA
  • Phone+1 (646) 233-6971
  • Fax+1 (302) 575-1642
  • Websitehttps://ibs.inc/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.